A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Advanes of Driving Genes in Bone Metastases from Lung Cancer
2019
Zhongliu Fangzhi Yanjiu
The skeleton is a common hematogenous metastasis site in lung cancer. The incidence of bone metastases in lung cancer patients is 30%-40%. It mainly occurs in the spine and the proximal trunk, including the spine, femur, ribs and sternum. The median overall survival time of these patients is 6-10 months, and the 1-year survival rate is 40%-50%. Exploring the molecular mechanism of bone metastasis has important guiding significance for the treatment. Some studies showed that driving genes in
doi:10.3971/j.issn.1000-8578.2019.18.1819
doaj:f80cd2661e0749658ebec083a014d08a
fatcat:musjv55mszbhvb6tghxf2ue7pq